Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Interest Expense

Cost of servicing the company's debt during the period.

Cellectis S.A.NASDAQ: CLLS

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense growth accelerates

Q1 FY2026 interest expense of $2.27M rose 18.7% year over year, ahead of the +11.7% change in trailing-twelve-month interest expense. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +28.9% a year.

Context

  • Interest expense amounted to 11.1% of revenue in FY2025, down 6.8 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.7% holds above the trailing-twelve-month pace of +11.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.27M+11.5% QoQ
Last fiscal yearDec 2025
$8.11M+8.8% YoY
LTMMar 2026
$8.49M+11.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.7%——
1 year+8.8%——
3-year CAGR+28.9%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
8.11M USD
Year-over-year change
+8.8%
4-year CAGR
+16.7%

Interest Expense vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.7% is the 3rd highest of 7, against a peer median of +1.3%.
  • Interest expense amounts to 12.5% of revenue for CLLS, versus a peer median of 0.0%.
CLLS Competitors
Interest Expense for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$9.64M USD—-38.1%—
CLLSCellectis S.A.LTM Mar 2026$8.49M USD+11.7%+28.9%12.5%
ANROAlto Neuroscience, Inc.LTM Mar 2026$2.42M USD+48.5%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.89M USD-1.1%+4.0%—
DBVTDBV Technologies S.A.LTM Mar 2026$656.17K USD+480.7%——
ACIUAC Immune S.A.LTM Mar 2026CHF 156.68K CHF+3.8%-18.7%4.2%
MREOMereo BioPharma Group plcLTM Mar 2026$94.83K USD-92.3%-57.7%19.0%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD——0.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
AMRNAmarin Corporation plcLTM Mar 2026$0 USD-100.0%-22.4%0.0%
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CLLS) —+1.3%-22.4%0.0%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.